Clinical Trials Logo

Side Effect clinical trials

View clinical trials related to Side Effect.

Filter by:

NCT ID: NCT06309641 Not yet recruiting - Anemia Clinical Trials

Methemoglobinemia Following Intravenous Iron Treatment

Start date: September 2024
Phase:
Study type: Observational

Methemoglobinemia as a side effect of treatment with intravenous iron has not previously been described. This study aims to assess methemoglobin levels in patients with anemia following treatment with intravenous iron, administered as ferric carboxymaltose or ferric derisomaltose.

NCT ID: NCT06133218 Completed - Breast Neoplasms Clinical Trials

Patient Reported Outcomes Using Mepitel Film During Radiotherapy

Start date: October 1, 2015
Phase: N/A
Study type: Interventional

Breast cancer patients in post-operative radiotherapy (RT) often experience acute skin reactions like erythema, pain, itching and oversensitivity. In 2014 a New Zealand randomized controlled trial (RCT) investigated the prophylactic use of safetac-based film, Mepitel Film, on half of the breast during RT compared to cream, resulting in significant differences in skin moist desquamation (0% vs. 26%). Despite changes in treatment modalities in Denmark toward lower total RT doses, the level of RT-induced skin toxicity could still be of great importance for the patients. The aim of this study is patient-reported symptoms and patient-reported experiences with the prophylactic use of Mepitel Film compared to standard cream treatment.

NCT ID: NCT06060886 Not yet recruiting - Schizophrenia Clinical Trials

Multidisciplinary Design to Optimize Schizophrenia Treatment Based on Multi-omics Data and Systems Biology Analysis

SchizOMICS
Start date: November 1, 2023
Phase: Phase 4
Study type: Interventional

SchizOMICS is a Phase IV, multicenter, dose-flexible, open-label, randomized controlled clinical trial to evaluate the efficacy and safety of aripiprazole versus paliperidone using multi-omics data in patients with a first psychotic episode. The trial will include a total of 244 patients, with two arms of treatment with paliperidone and aripiprazole (1:1). The main objectives of the study are: 1. To compare the efficacy and safety of aripiprazole and paliperidone in the treatment of first episode psychosis (FEP) subjects in real-world clinical settings at 3 months. 2. To elucidate whether non-responders after 3 months of adequate treatment may display different molecular signatures at baseline based on multi omics data and systems biology analysis. 3. To uncover whether the appearance of side effects after 1 year of adequate treatment may be related to different molecular signatures based on multi-omics data and lifestyle phenotype using systems biology analysis.

NCT ID: NCT05958823 Recruiting - Postoperative Pain Clinical Trials

Effects of Serratus Anterior Plan Block (SAP) and Pectoralis Blocks (PECS I-II) After Open Heart Surgery

Start date: September 1, 2022
Phase: N/A
Study type: Interventional

The effects of anterior chest wall blocks (PECS and SAP will be used in this study) performed for postoperative analgesia on pain scores (to be checked with visual analogue scale (VAS), opioid consumption, length of hospital stay, mobilization time, side effects and complications in the postoperative period will be examined.

NCT ID: NCT05861076 Active, not recruiting - Side Effect Clinical Trials

Moringa Powder Acceptability Trial Among Healthy Adults

Start date: January 3, 2023
Phase: N/A
Study type: Interventional

The study is a randomized acceptability trial involving the provision of three different doses of Moringa powder to be consumed daily by study participants.

NCT ID: NCT05743985 Active, not recruiting - Clinical trials for Inflammatory Response

Efficacy and Safety of Hemp-derived, Full Spectrum Cannabigerol (CBG) in Adults

Start date: August 1, 2022
Phase: N/A
Study type: Interventional

The goal of this observational study is to provide exploratory research into the in vivo physiological and psychological effects, if any, of cannabigerol (CBG) in healthy human adults age 21 or over. The main questions it aims to answer are: - What effect, if any, does daily oral consumption of 50mg of full spectrum CBG have on the mental, physical, and emotional wellbeing of healthy individuals, as measured by self-report Medical Symptom Questionnaire and 36-Item Short Form Health Survey scores? - Is CBG effective at reducing inflammation in the body, as measured by HSCRP, ESR, and PSA inflammatory markers? - Do age, gender, weight, or state of body inflammation have an effect on the perceived efficacy of CBG? - What adverse effects, if any, are associated with CBG use? Over the course of the 12-week study, participants will: - Take baseline MSQ and SF-36 surveys, as well as a clinical visit with blood draws for HSCRP, ESR, and PSA testing - Consume one (1) 50mg capsule of full spectrum CBG daily by mouth with food for 8 weeks, followed by a 4-week washout period - Complete biweekly SF-36 surveys as well as MSQ surveys every 4 weeks - Attend a clinical visit every 4 weeks for clinical observation and blood draws for HSCRP, ESR, and PSA (male subjects)

NCT ID: NCT05542849 Completed - Tolerance Clinical Trials

The Efficacy and Tolerability of Acarbose in Healthy Individuals

Start date: August 10, 2022
Phase: Phase 4
Study type: Interventional

A Prospective Trial for Acarbose in Healthy Individuals Assessing Safety and Efficacy in Reducing Glucose Spikes After Carbohydrate Consumption.

NCT ID: NCT05421962 Completed - Pain Clinical Trials

Analgosedation for Elective Colonoscopy

Start date: January 1, 2020
Phase: Phase 1
Study type: Interventional

Aim: The aim of the study was to to compare the analgesic effects of ketamine over fentanyl combined with propofol in analgesia-based elective colonoscopy with purpose of patient safety and satisfaction. Methods: This is a double-blinded prospective randomized controlled trial. Ninety patients were included and randomized to either fentanyl-propofol (Group FP, n: 30), ketamine-propofol (Group KP, n: 30) or propofol-control group (Group C, n: 30). Group FP patients received fentanyl and propofol, Group KP received ketamine and propofol and Group C, propofol. In all groups, incremental doses of propofol were used to maintain a Ramsay sedation score (RSS) of 5. Respiratory depression, hemodynamic parameters were monitored for the first minute and every 5 minutes during endoscopy. Fifteen minutes after the procedure, the degree of pain was assessed using a visual analog scale (VAS), the quality of recovery according to the Aldrete score (ARS), complications during and after the procedure and additional doses of propofol were recorded.

NCT ID: NCT05155202 Active, not recruiting - Clinical trials for Hypoxemic Respiratory Failure

Clinical Relevance of Nicardipine Induced Hypoxemia in the Intensive Care Unit

ECRHIN-ICU
Start date: November 15, 2021
Phase:
Study type: Observational

In the context of postoperative hypertension in the intensive care units, or after resusitation of hypertensive patients, intravenous antihypertensive drugs are often used. Among those drugs, Nicardipine is an effective drug, but with side effects such as inhibition of pulmonary vasoconstriction. Only preclinical studies have investigated the pathophysiology of this mechanism, and no clinical study have proven its clinical relevance. The aim of this study is to establish the incidence of Nicardipine induced hypoxemia and to compare it to another antihypertensive agent, Urapidil.

NCT ID: NCT05055648 Recruiting - Esophageal Cancer Clinical Trials

PROton Versus Photon Therapy for Esophageal Cancer - a Trimodality Strategy

PROTECT
Start date: May 1, 2022
Phase: N/A
Study type: Interventional

The PROTECT trial will test the hypothesis that proton (PT) -enabled radiation dose reductions to sensitive, normal tissues will result in lower rates of treatment-related pulmonary complications in esophageal cancer compared to standard photon therapy (XT).